## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.4% below STRENGTH zone (3.0-6.0%); PEG 1.51 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Korea Investment CORP Sells 60,900 Shares of Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251203T160822 | Neutral | Relevance: 99%
-  Korea Investment CORP reduced its stake in Hologic, Inc. by 43.6% in the second quarter, selling 60,900 shares and retaining 78,931 shares valued at $5.14 million. This move comes as other institutional investors have either increased or initiated positions in Hologic, while company insiders, including CEO Stephen P. Macmillan and Director Christiana Stamoulis, have also sold significant shares. Hologic recently reported robust earnings, beating estimates with EPS of $1.13 and revenue of $1.05 billion, leading to a consensus "Hold" rating from analysts with an average price target of $79.67.

**2. Invesco Ltd. Buys 3,505,828 Shares of Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251205T122304 | Neutral | Relevance: 99%
- Invesco Ltd. significantly increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 72.5% in the second quarter, purchasing an additional 3,505,828 shares. This acquisition brings Invesco's total holdings to 8,340,785 shares, valued at $543,486,000, representing approximately 3.75% of the company. Other institutional investors also adjusted their positions, and Hologic reported strong quarterly earnings, beating analyst estimates.

**3. Russell Investments Group Ltd. Sells 63,796 Shares of Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251204T033809 | Neutral | Relevance: 98%
-  Russell Investments Group Ltd. reduced its stake in Hologic, Inc. by 28.5% in the second quarter, selling 63,796 shares and now holding 159,770 shares valued at $10.41 million. This comes as Hologic beat Q1 earnings estimates with $1.13 EPS and $1.05 billion revenue while insiders, including CEO Stephen P. Macmillan, also made significant share sales. The company currently holds an average analyst "Hold" rating with a target price of $79.67.

**4. Why Is Hologic (HOLX) Up 1% Since Last Earnings Report?**
- Source: Nasdaq | 20251203T170958 | Somewhat-Bullish | Relevance: 98%
-  Hologic (HOLX) shares have increased by 1% since its last earnings report, outperforming the S&P 500. The company surpassed Q4 earnings and revenue estimates, reporting adjusted EPS of $1.13 and revenues of $1.05 billion. Estimates for the stock have been trending upward, with Hologic currently holding a Zacks Rank #3 (Hold).

**5. Lido Advisors LLC Invests $1.27 Million in Hologic, Inc. $HOLX**
- Source: MarketBeat | 20251205T114943 | Somewhat-Bullish | Relevance: 98%
- Lido Advisors LLC has acquired a new stake of 19,413 shares in Hologic, Inc. (NASDAQ:HOLX) valued at approximately $1.27 million in the second quarter. Other institutional investors have also adjusted their holdings in Hologic, with the stock currently having 94.73% institutional ownership. Analysts maintain a consensus "Hold" rating for Hologic with an average price target of $79.67.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $76 | $69 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.51 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Analyst sentiment positive (1 raises, avg +10%). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $80.31 |
| Short Interest | 2.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.51 |
| Forward P/E | 15.0 |
| Current P/E | 16.4 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.4% (minimal 5-day change). Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.45% (CS: 39) | Neutral |
| RSI_14 | 68.2 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 1.039x | Above |
| vs SMA200 | 1.148x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.97
- **Stop Loss:** $74.09 (1.2% risk)
- **Target:** $75.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 568
- **Position Value:** $42,582.96
- **Portfolio %:** 42.58%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*